68,081 Shares in Xylem Inc. $XYL Bought by Soltis Investment Advisors LLC

Soltis Investment Advisors LLC acquired a new stake in Xylem Inc. (NYSE:XYL) in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 68,081 shares of the industrial products company’s stock, valued at approximately $6,895,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Choreo LLC purchased a new position in Xylem in the 3rd quarter worth $248,000. North Star Investment Management Corp. lifted its stake in Xylem by 21.4% in the third quarter. North Star Investment Management Corp. now owns 1,701 shares of the industrial products company’s stock worth $172,000 after purchasing an additional 300 shares during the last quarter. William Mack & Associates Inc. purchased a new stake in Xylem during the third quarter valued at about $25,000. Generali Asset Management SPA SGR boosted its position in Xylem by 2.0% during the third quarter. Generali Asset Management SPA SGR now owns 14,248 shares of the industrial products company’s stock valued at $1,443,000 after buying an additional 273 shares during the period. Finally, Oppenheimer & Co. Inc. grew its stake in shares of Xylem by 5.4% during the third quarter. Oppenheimer & Co. Inc. now owns 98,228 shares of the industrial products company’s stock valued at $9,948,000 after buying an additional 5,023 shares during the last quarter. Institutional investors own 87.96% of the company’s stock.

Insider Activity

In other Xylem news, Director D Koch bought 11,000 shares of the business’s stock in a transaction that occurred on Thursday, October 29th. The shares were bought at an average cost of $89.60 per share, with a total value of $985,600.00. Following the completion of the purchase, the director directly owned 12,247 shares of the company’s stock, valued at $1,097,331.20. This trade represents a 882.12% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 0.32% of the stock is owned by insiders.

Xylem Trading Up 2.8%

Shares of XYL opened at $90.74 on Friday. The stock has a market capitalization of $20.81 billion, a P/E ratio of 20.08, a PEG ratio of 1.47 and a beta of 1.00. The company has a quick ratio of 1.24, a current ratio of 1.39 and a debt-to-equity ratio of 0.23. The firm has a fifty day simple moving average of $105.47 and a two-hundred day simple moving average of $117.80. Xylem Inc. has a twelve month low of $87.40 and a twelve month high of $154.27.

Xylem (NYSE:XYL) last announced its quarterly earnings results on Tuesday, October 27th. The industrial products company reported $1.44 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.45 by ($0.01). Xylem had a return on equity of 12.06% and a net margin of 11.94%. The firm had revenue of $2.20 billion during the quarter, compared to the consensus estimate of $2.28 billion. During the same period last year, the business earned $1.37 EPS. Xylem’s revenue was down 3.0% on a year-over-year basis. On average, research analysts anticipate that Xylem Inc. will post 5.47 EPS for the current year.

Xylem Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, September 24th. Stockholders of record on Thursday, August 27th were issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 1.9%. The ex-dividend date was Thursday, August 27th. Xylem’s dividend payout ratio is currently 40.95%.

More Xylem News

Here are the key news stories impacting Xylem this week:

• Positive Sentiment: Director D. Christian Koch purchased 11,000 shares worth approximately $985,600, substantially increasing his direct ownership. The transaction may signal confidence that the recent decline has created an attractive entry point. SEC insider trading filing
• Positive Sentiment: Options activity was notably bullish on Thursday, with traders buying 20,508 call options—roughly 771% above typical volume—suggesting some investors are positioning for a rebound.
• Positive Sentiment: RBC Capital reaffirmed its buy rating, while its broader analyst coverage set a “moderate buy” rating and a $125 price target. Other firms, including Citigroup, BNP Paribas Exane, Stifel and Oppenheimer, maintained positive ratings despite lowering their targets. RBC rating article
• Neutral Sentiment: Xylem announced divestitures and a new three-segment structure, which could improve strategic focus and portfolio efficiency but may create near-term execution and transition risks. Xylem restructuring article
• Negative Sentiment: Third-quarter revenue was $2.20 billion, below the $2.28 billion consensus estimate, while adjusted EPS of $1.44 narrowly missed expectations. Revenue declined 3% year over year, and Xylem cut its 2026 outlook. Xylem earnings article
• Negative Sentiment: Barclays downgraded Xylem to equal weight from overweight, while JPMorgan moved to underweight and UBS lowered its target to $99 with a neutral rating. Stifel also cut its target to $114. These actions highlight persistent concerns about near-term growth and valuation. Barclays downgrade article
• Negative Sentiment: Unusual put-option activity, with put volume several times above average, and a law firm’s announced investigation into potential securities-law violations add further risk and uncertainty. Xylem investigation notice

Wall Street Analysts Forecast Growth

XYL has been the topic of a number of recent research reports. Royal Bank Of Canada reduced their price objective on Xylem from $135.00 to $125.00 and set an “outperform” rating on the stock in a research note on Wednesday. Stifel Nicolaus lowered their target price on Xylem from $141.00 to $114.00 and set a “buy” rating for the company in a research note on Wednesday. Oppenheimer dropped their target price on Xylem from $150.00 to $135.00 and set an “outperform” rating for the company in a report on Wednesday. BNP Paribas Exane dropped their target price on Xylem from $145.00 to $135.00 and set an “outperform” rating for the company in a report on Wednesday. Finally, Barclays lowered Xylem from an “overweight” rating to an “equal weight” rating and reduced their price target for the stock from $139.00 to $104.00 in a research report on Wednesday. Nine research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $121.31.

About Xylem

Xylem Inc (NYSE: XYL) is a global water technology company that develops products and services for the transportation, treatment, testing and efficient use of water and wastewater. Its offerings support municipal water and wastewater utilities, industrial customers, commercial facilities and residential applications.

The company’s products and solutions include water and wastewater pumps, treatment systems, dewatering equipment, smart meters, monitoring and control technologies, leak detection tools, and data-driven analytics.